Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q504Q3

UPID:
PAN2_HUMAN

ALTERNATIVE NAMES:
Inactive ubiquitin carboxyl-terminal hydrolase 52; PAB1P-dependent poly(A)-specific ribonuclease; Poly(A)-nuclease deadenylation complex subunit 2

ALTERNATIVE UPACC:
Q504Q3; O75189; Q76E12; Q8IVE1

BACKGROUND:
PAN2, functioning within the PAN2-PAN3 deadenylation complex, is integral to general and miRNA-mediated mRNA turnover. By specifically shortening poly(A) tails, it enables mRNA degradation pathways, including the CCR4-NOT complex and exonucleolytic degradation. Beyond its role in mRNA turnover, PAN2 is essential for regulating HIF1A-mediated hypoxic responses, highlighting its importance in cellular adaptation to oxygen availability.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of PAN2-PAN3 deadenylation complex catalytic subunit PAN2 reveals potential avenues for therapeutic intervention.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.